AC

Ambarish Chatterjee

Active Director Director DIN 06914255
DIN 06914255 First appointment Nov 2014 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since Nov 2014
Shareholding value •••• Premium profile

About Ambarish Chatterjee

Data last updated:

Ambarish Chatterjee is a Director at Impact Therapeutics Limited (since 2024), Director at Skinbook Laboratories India Private Limited (since 2024) and Director at Skinbook Lab India Limited (since 2023). The companies operate in Pharma, E-Commerce and Household Services. The 2 current companies with reported revenue have a combined latest revenue of ₹1,500 Cr; the largest is Impact Therapeutics Limited at ₹1,499 Cr (FY 2024). Earlier, Ambarish Chatterjee was an Additional Director at Curever Pharma Private Limited (2021–2022) and Director at Naos Skin Care India Private Limited (2014–2018) and 1 more.

DIN 06914255
Primary Designation Director
Industry Pharma
First Appointment 14 Nov 2014
Oldest Company Age 15 yrs
Largest company Impact Therapeutics Limited · ₹1,499 Cr (FY 2024)
Combined revenue ₹1,500 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Impact Therapeutics Limited U51909MH2010PLC211564
Director25 Jan 20242010₹1,499 Cr (FY 2024)Active
Director11 Jan 20242018₹53.5 Lakh (FY 2024)Active
Skinbook Lab India Limited U96020MH2023PLC401887
Director28 Apr 20232023Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Curever Pharma Private Limited U24230MH2021PTC353725
Additional Director15 Feb 20212021₹56.8 Lakh (FY 2025)Active
Naos Skin Care India Private Limited U74999MH2014FTC259308
Director14 Nov 20142014₹83.25 Cr (FY 2023)Active
Designated Partner16 Aug 20182017Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Ambarish Chatterjee

Directorship timeline

Open interactive timeline →
Skinbook Lab India Limited
Impact Therapeutics Limited
Skinbook Laboratories India Private Limited
Curever Pharma Private Limited
Premium access

Shareholding and investment profile for Ambarish Chatterjee

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ambarish Chatterjee

Ambarish Chatterjee currently holds 3 directorships: Impact Therapeutics Limited (Director, since 25 Jan 2024, revenue ₹1,499 Cr (FY 2024)); Skinbook Laboratories India Private Limited (Director, since 11 Jan 2024, revenue ₹53.5 Lakh (FY 2024)); Skinbook Lab India Limited (Director, since 28 Apr 2023).

Ambarish Chatterjee was first appointed on 14 Nov 2014 as Director at Naos Skin Care India Private Limited. The most recent appointment on record is 25 Jan 2024 at Impact Therapeutics Limited.

The 2 current companies of Ambarish Chatterjee that report revenue have a combined latest revenue of ₹1,500 Cr: Impact Therapeutics Limited ₹1,499 Cr (FY 2024); Skinbook Laboratories India Private Limited ₹53.5 Lakh (FY 2024).

Ambarish Chatterjee held 3 earlier board appointments: Curever Pharma Private Limited (Additional Director, 15 Feb 2021 to 21 Jan 2022); Naos Skin Care India Private Limited (Director, 14 Nov 2014 to 01 Apr 2018); Aim Smart Wealth Llp (Designated Partner, 16 Aug 2018 to 28 Aug 2019).

The current boards of Ambarish Chatterjee's companies include Pooja Rajan Ambure (Impact Therapeutics Limited), Rakesh Grihpati Singh (Impact Therapeutics Limited), Peu Ambarish Chatterjee (Skinbook Laboratories India Private Limited), Aahan Chatterjee (Skinbook Lab India Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available